ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,191.29
0.60%
Dow Jones
38,834.86
0.15%
Gold vs US Dollar
2,329.655
0.40%
Brent Oil
84.705
0.96%
Bitcoin
64,365.55
-3.19%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. NeuroBo Pharmaceuticals Inc (NRBO) Share Price

NRBO NeuroBo Pharmaceuticals Inc

3.715
-0.1122 (-2.93%)
Last Updated: 20:57:01
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 NeuroBo Pharmaceuticals Inc NASDAQ:NRBO NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -0.1122 -2.93 3.715 3.66 3.85 3.93 3.63 3.81 18,580 19:57:01   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -12.47M -2.5703 -1.41 17.61M
 Type  Size  Price  Time  Units 
 9 1 3.85 19:59:34 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore NRBO News
08/06/202400:26EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
07/06/202421:06EDGAR2Form 8-K - Current report
22/05/202413:30EDGAR2Form 8-K - Current report
22/05/202413:01PRNUSNeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone
09/05/202414:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/05/202413:05EDGAR2Form 8-K - Current report
09/05/202413:01PRNUSNeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Period
Draw mode
Data Downloads for NRBO

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest NeuroBo Pharmaceuticals Inc Articles